All In Biotech

Drug Trial Radar · NCT00389779

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo (Protocol DAR-312)

Last checked: Nov 20, 2026Latest source record: Mar 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 849 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

849

Actual

Start

Sep 2006

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Oct 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic and diastolic hypertension despite treatment with full doses of three or more antihypertensive drugs, including a diuretic. Subjects will be randomized to darusentan (optimized dose), an active comparator, or placebo, administered orally. The treatment period for this trial is 14 weeks.

Conditions

  • Hypertension

Interventions

  • DarusentanDrug

    Darusentan capsules administered orally once daily

  • GuanfacineDrug

    Guanfacine capsules administered orally once daily

  • Darusentan PlaceboDrug

    Placebo to match darusentan administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometryTime frame: Baseline to Week 14

Locations

147 sites in 10 countries. Site status is shown where the registry gives one.

  • Alabama Internal Medicine, PC

    Birmingham, Alabama

  • Greystone Medical Research, LLC

    Birmingham, Alabama

  • The Heart Center, PC

    Huntsville, Alabama

  • Mulberry Medical Associates, PC

    Montgomery, Alabama

  • Arizona Center for Clinical Research

    Glendale, Arizona

  • Cardiovascular Consultants, Ltd.

    Glendale, Arizona

  • Lovelace Scientific Resources, Inc

    Phoenix, Arizona

  • Cochise Clinical Research

    Sierra Vista, Arizona

  • Southwest Heart

    Tucson, Arizona

  • HealthFirst Physician of AR, PA dba Convenient Care Clinic

    Hot Springs, Arkansas

  • NEA Clinic

    Jonesboro, Arkansas

  • Arkansas Primary Care Clinic, PA

    Little Rock, Arkansas

  • Medical Investigations Inc.

    Little Rock, Arkansas

  • Highgrove Medical Center

    Bakersfield, California

  • Central Cardiology Medical Clinic

    Bakersfield, California

  • Impact Clinical Trials

    Beverly Hills, California

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California

  • Rancho Cucamonga Clinical Trials

    Rancho Cucamonga, California

  • Pacific Heart Institute

    Santa Monica, California

  • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

    Torrance, California

  • Aurora Denver Cardiology Associates

    Aurora, Colorado

  • Aurora Denver Cardiology Associates

    Aurora, Colorado

  • Clinical Research of South Florida

    Coral Gables, Florida

  • Doctors Medical Center of Walton County

    DeFuniak Springs, Florida

  • Broward General Medical Center

    Fort Lauderdale, Florida

  • Maxine Hamilton, MD, PA

    Fort Lauderdale, Florida

  • St. John's Center for Clinical Research

    Jacksonville, Florida

  • Private Practice of Dr. Bridget Bellingar

    Largo, Florida

  • A+ Research Inc.

    Miami, Florida

  • AppleMed Research, Inc.

    Miami, Florida

  • Internal Medicine Associates of South Florida

    North Miami Beach, Florida

  • Ormond Medical Arts Pharmaceutical Research center

    Ormond Beach, Florida

  • Northwest Florida Heart Group, PA - Research Dept

    Pensacola, Florida

  • Cardiovascular Center of Sarasota

    Sarasota, Florida

  • Suncoast Cardiovascular Research, Inc.

    St. Petersburg, Florida

  • Tampa Bay Nephrology Associates, PL

    Tampa, Florida

  • Orlando Rangel, MD, PA

    Tampa, Florida

  • Medical College of Georgia

    Augusta, Georgia

  • AMR Research Associates, LLC

    Bogart, Georgia

  • Atlanta Vascular Research Foundation

    Tucker, Georgia

Showing 40 of 147 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.